Veru plans to continue development of the oral drug, sabizabulin, in late-stage studies with high-risk hospitalized influenza patients and COVID-19 patients. It expects to report interim data from the COVID-19 trial next year.
TILDA SWINTON IS DONE WITH COVID MANDATES: 'I'M NOT WEARING A MASK'
Drug developer Veru Inc is going to proceed with a late-stage study of a COVID-19 pill despite FDA snub.
The company said it was planning to meet the U.S. Food and Drug Administration soon and will communicate details of the late-stage trial after the meeting.
Additionally, Veru will stop the development of two of its other cancer drug candidates - VERU-100 and zuclomiphene - which it was testing in mid-stage studies for various indications.
Shares of the company rose nearly 3% to $2.09 in afternoon trade.